Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 149

1.

Reply to Rodrigues et al.: Increasing Physical Activity in Daily Life in Chronic Obstructive Pulmonary Disease: To Solve the Puzzle, Every Piece Counts.

Nolan CM, Maddocks M, Canavan JL, Jones SE, Delogu V, Kaliaraju D, Banya W, Kon SSC, Polkey MI, Man WD.

Am J Respir Crit Care Med. 2018 Apr 15;197(8):1089-1090. doi: 10.1164/rccm.201711-2213LE. No abstract available.

PMID:
29206054
2.

Phenotypic characteristics associated with slow gait speed in idiopathic pulmonary fibrosis.

Nolan CM, Maddocks M, Maher TM, Canavan JL, Jones SE, Barker RE, Patel S, Jacob J, Cullinan P, Man WD.

Respirology. 2018 May;23(5):498-506. doi: 10.1111/resp.13213. Epub 2017 Nov 14.

PMID:
29139195
3.

The Epworth Sleepiness Scale: Minimum Clinically Important Difference in Obstructive Sleep Apnea.

Patel S, Kon SSC, Nolan CM, Barker RE, Simonds AK, Morrell MJ, Man WD.

Am J Respir Crit Care Med. 2018 Apr 1;197(7):961-963. doi: 10.1164/rccm.201704-0672LE. No abstract available.

PMID:
28961021
4.

Validity, responsiveness and minimum clinically important difference of the incremental shuttle walk in idiopathic pulmonary fibrosis: a prospective study.

Nolan CM, Delogu V, Maddocks M, Patel S, Barker RE, Jones SE, Kon SSC, Maher TM, Cullinan P, Man WD.

Thorax. 2017 Sep 7. pii: thoraxjnl-2017-210589. doi: 10.1136/thoraxjnl-2017-210589. [Epub ahead of print]

PMID:
28883090
5.

Reply to Sasso et al.: Are All Steps Created Equal? Revisiting Pedometer Use during Pulmonary Rehabilitation for Individuals Living with Chronic Obstructive Pulmonary Disease.

Nolan CM, Maddocks M, Canavan JL, Jones SE, Delogu V, Kaliaraju D, Banya W, Kon SSC, Polkey MI, Man WD.

Am J Respir Crit Care Med. 2018 Feb 1;197(3):406-409. doi: 10.1164/rccm.201707-1513LE. No abstract available.

PMID:
28787177
6.

Gait speed and pedestrian crossings in COPD.

Nolan CM, Kon SSC, Patel S, Jones SE, Barker RE, Polkey MI, Maddocks M, Man WD.

Thorax. 2018 Feb;73(2):191-192. doi: 10.1136/thoraxjnl-2017-210173. Epub 2017 May 5.

7.

Simple functional tests in COPD: stand up and be counted!

Maddocks M, Nolan CM, Man WD.

Eur Respir J. 2017 Mar 2;49(3). pii: 1700104. doi: 10.1183/13993003.00104-2017. Print 2017 Mar. No abstract available.

PMID:
28254769
8.

Pedometer Step Count Targets during Pulmonary Rehabilitation in Chronic Obstructive Pulmonary Disease. A Randomized Controlled Trial.

Nolan CM, Maddocks M, Canavan JL, Jones SE, Delogu V, Kaliaraju D, Banya W, Kon SSC, Polkey MI, Man WD.

Am J Respir Crit Care Med. 2017 May 15;195(10):1344-1352. doi: 10.1164/rccm.201607-1372OC.

9.

Physical frailty and pulmonary rehabilitation in COPD: a prospective cohort study.

Maddocks M, Kon SS, Canavan JL, Jones SE, Nolan CM, Labey A, Polkey MI, Man WD.

Thorax. 2016 Nov;71(11):988-995. doi: 10.1136/thoraxjnl-2016-208460. Epub 2016 Jun 12.

10.

The EQ-5D-5L health status questionnaire in COPD: validity, responsiveness and minimum important difference.

Nolan CM, Longworth L, Lord J, Canavan JL, Jones SE, Kon SS, Man WD.

Thorax. 2016 Jun;71(6):493-500. doi: 10.1136/thoraxjnl-2015-207782. Epub 2016 Mar 30.

11.

Neuromuscular electrical stimulation to improve exercise capacity in patients with severe COPD: a randomised double-blind, placebo-controlled trial.

Maddocks M, Nolan CM, Man WD, Polkey MI, Hart N, Gao W, Rafferty GF, Moxham J, Higginson IJ.

Lancet Respir Med. 2016 Jan;4(1):27-36. doi: 10.1016/S2213-2600(15)00503-2. Epub 2015 Dec 15.

12.

Gait speed and readmission following hospitalisation for acute exacerbations of COPD: a prospective study.

Kon SS, Jones SE, Schofield SJ, Banya W, Dickson MJ, Canavan JL, Nolan CM, Haselden BM, Polkey MI, Cullinan P, Man WD.

Thorax. 2015 Dec;70(12):1131-7. doi: 10.1136/thoraxjnl-2015-207046. Epub 2015 Aug 17.

13.

Functionally Relevant Cut Point for Isometric Quadriceps Muscle Strength in Chronic Respiratory Disease.

Canavan JL, Maddocks M, Nolan CM, Jones SE, Kon SS, Clark AL, Polkey MI, Man WD.

Am J Respir Crit Care Med. 2015 Aug 1;192(3):395-7. doi: 10.1164/rccm.201501-0082LE. No abstract available.

14.

Does pulmonary rehabilitation reduce peripheral blood pressure in patients with chronic obstructive pulmonary disease?

Canavan JL, Kaliaraju D, Nolan CM, Clark AL, Jones SE, Kon SS, Polkey MI, Man WD.

Chron Respir Dis. 2015 Aug;12(3):256-63. doi: 10.1177/1479972315587515. Epub 2015 May 25.

15.

Sarcopenia definitions: where to draw the line? Response to Scarlata et al.

Maddocks M, Jones SE, Kon SS, Canavan JL, Nolan CM, Clark AL, Polkey MI, Man WD.

Thorax. 2015 Jul;70(7):694. doi: 10.1136/thoraxjnl-2015-207041. Epub 2015 Apr 8. No abstract available.

16.

Muscular dystrophy in the Japanese Spitz: an inversion disrupts the DMD and RPGR genes.

Atencia-Fernandez S, Shiel RE, Mooney CT, Nolan CM.

Anim Genet. 2015 Apr;46(2):175-84. doi: 10.1111/age.12266. Epub 2015 Jan 23.

PMID:
25644216
17.

Bioelectrical impedance phase angle relates to function, disease severity and prognosis in stable chronic obstructive pulmonary disease.

Maddocks M, Kon SS, Jones SE, Canavan JL, Nolan CM, Higginson IJ, Gao W, Polkey MI, Man WD.

Clin Nutr. 2015 Dec;34(6):1245-50. doi: 10.1016/j.clnu.2014.12.020. Epub 2015 Jan 7.

18.

Sarcopenia in COPD: prevalence, clinical correlates and response to pulmonary rehabilitation.

Jones SE, Maddocks M, Kon SS, Canavan JL, Nolan CM, Clark AL, Polkey MI, Man WD.

Thorax. 2015 Mar;70(3):213-8. doi: 10.1136/thoraxjnl-2014-206440. Epub 2015 Jan 5.

PMID:
25561517
19.

Clinical COPD Questionnaire in patients with chronic respiratory disease.

Canavan JL, Dilaver D, Clark AL, Jones SE, Nolan CM, Kon SS, Man WD.

Respirology. 2014 Oct;19(7):1006-12. doi: 10.1111/resp.12350. Epub 2014 Aug 14.

20.

What the 4-metre gait speed measures and why it cannot replace functional capacity tests.

Kon SS, Canavan JL, Nolan CM, Clark AL, Jones SE, Cullinan P, Polkey MI, Man WD.

Eur Respir J. 2014 Jun;43(6):1820-2. doi: 10.1183/09031936.00222013. No abstract available.

21.

Major histocompatibility complex class II alleles and haplotypes associated with non-suppurative meningoencephalitis in greyhounds.

Shiel RE, Kennedy LJ, Nolan CM, Mooney CT, Callanan JJ.

Tissue Antigens. 2014 Sep;84(3):271-6. doi: 10.1111/tan.12365. Epub 2014 May 23.

PMID:
24851745
22.

Minimum clinically important difference for the COPD Assessment Test: a prospective analysis.

Kon SS, Canavan JL, Jones SE, Nolan CM, Clark AL, Dickson MJ, Haselden BM, Polkey MI, Man WD.

Lancet Respir Med. 2014 Mar;2(3):195-203. doi: 10.1016/S2213-2600(14)70001-3. Epub 2014 Feb 4.

23.

The clinical chronic obstructive pulmonary disease questionnaire: cut point for GOLD 2013 classification.

Kon SS, Canavan JL, Nolan CM, Jones SE, Clark AL, Polkey MI, Man WD.

Am J Respir Crit Care Med. 2014 Jan 15;189(2):227-8. doi: 10.1164/rccm.201310-1805LE. No abstract available.

24.

The 4-metre gait speed in COPD: responsiveness and minimal clinically important difference.

Kon SS, Canavan JL, Nolan CM, Clark AL, Jones SE, Cullinan P, Polkey MI, Man WD.

Eur Respir J. 2014 May;43(5):1298-305. doi: 10.1183/09031936.00088113. Epub 2013 Oct 31.

25.

The Clinical COPD Questionnaire: response to pulmonary rehabilitation and minimal clinically important difference.

Kon SS, Dilaver D, Mittal M, Nolan CM, Clark AL, Canavan JL, Jones SE, Polkey MI, Man WD.

Thorax. 2014 Sep;69(9):793-8. doi: 10.1136/thoraxjnl-2013-204119. Epub 2013 Oct 22.

PMID:
24149828
26.

The five-repetition sit-to-stand test as a functional outcome measure in COPD.

Jones SE, Kon SS, Canavan JL, Patel MS, Clark AL, Nolan CM, Polkey MI, Man WD.

Thorax. 2013 Nov;68(11):1015-20. doi: 10.1136/thoraxjnl-2013-203576. Epub 2013 Jun 19.

PMID:
23783372
27.

Reliability and validity of 4-metre gait speed in COPD.

Kon SS, Patel MS, Canavan JL, Clark AL, Jones SE, Nolan CM, Cullinan P, Polkey MI, Man WD.

Eur Respir J. 2013 Aug;42(2):333-40. doi: 10.1183/09031936.00162712. Epub 2012 Dec 6.

28.

An exon splice enhancer primes IGF2:IGF2R binding site structure and function evolution.

Williams C, Hoppe HJ, Rezgui D, Strickland M, Forbes BE, Grutzner F, Frago S, Ellis RZ, Wattana-Amorn P, Prince SN, Zaccheo OJ, Nolan CM, Mungall AJ, Jones EY, Crump MP, Hassan AB.

Science. 2012 Nov 30;338(6111):1209-13. doi: 10.1126/science.1228633.

29.

Tuberculosis elimination in the United States: an achievable goal or an illusion?

Reves RR, Nolan CM.

Am J Respir Crit Care Med. 2012 Aug 1;186(3):i-iii. doi: 10.1164/rccm.201206-1039ED. No abstract available.

PMID:
22855550
30.

Unique topographic distribution of greyhound nonsuppurative meningoencephalitis.

Terzo E, McConnell JF, Shiel RE, McAllister H, Behr S, Priestnall SL, Smith KC, Nolan CM, Callanan JJ.

Vet Radiol Ultrasound. 2012 Nov-Dec;53(6):636-42. doi: 10.1111/j.1740-8261.2012.01963.x. Epub 2012 Jun 29.

PMID:
22742427
31.

Clinical and clinicopathological features of non-suppurative meningoencephalitis in young greyhounds in Ireland.

Shiel RE, Mooney CT, Brennan SF, Nolan CM, Callanan JJ.

Vet Rec. 2010 Aug 28;167(9):333-7. doi: 10.1136/vr.c4248.

PMID:
20802187
32.

Epigenetics and gene expression.

Gibney ER, Nolan CM.

Heredity (Edinb). 2010 Jul;105(1):4-13. doi: 10.1038/hdy.2010.54. Epub 2010 May 12. Review.

33.

Insulin-like growth factor-2 regulates early neural and cardiovascular system development in zebrafish embryos.

Hartnett L, Glynn C, Nolan CM, Grealy M, Byrnes L.

Int J Dev Biol. 2010;54(4):573-83. doi: 10.1387/ijdb.092922lh.

34.

Regulation of expression of zebrafish (Danio rerio) insulin-like growth factor 2 receptor: implications for evolution at the IGF2R locus.

Tsalavouta M, Astudillo O, Byrnes L, Nolan CM.

Evol Dev. 2009 Sep-Oct;11(5):546-58. doi: 10.1111/j.1525-142X.2009.00361.x.

PMID:
19754711
35.

Genomic imprinting in Canis familiaris.

Nolan CM, O'Sullivan FM, Brabazon DC, Callanan JJ.

Reprod Domest Anim. 2009 Jul;44 Suppl 2:16-21. doi: 10.1111/j.1439-0531.2009.01387.x. Review.

PMID:
19754530
36.

Imprinted expression of the canine IGF2R, in the absence of an anti-sense transcript or promoter methylation.

O'Sullivan FM, Murphy SK, Simel LR, McCann A, Callanan JJ, Nolan CM.

Evol Dev. 2007 Nov-Dec;9(6):579-89.

PMID:
17976054
37.

Field assessment of a model tuberculosis outbreak response plan for low-incidence areas.

Freimanis Hance L, Steingart KR, Hahn CG, Pascopella L, Nolan CM.

BMC Public Health. 2007 Oct 26;7:307.

38.

Circulating insulin-like growth factors and related binding proteins are selectively altered in amyotrophic lateral sclerosis and multiple sclerosis.

Hosback S, Hardiman O, Nolan CM, Doyle MA, Gorman G, Lynch C, O'Toole O, Jakeman P.

Growth Horm IGF Res. 2007 Dec;17(6):472-9. Epub 2007 Aug 13.

PMID:
17697791
39.

1H NMR investigation of thermally triggered insulin release from poly(N-isopropylacrylamide) microgels.

Nolan CM, Gelbaum LT, Lyon LA.

Biomacromolecules. 2006 Oct;7(10):2918-22.

PMID:
17025370
40.

An official ATS statement: hepatotoxicity of antituberculosis therapy.

Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, Peloquin CA, Gordin FM, Nunes D, Strader DB, Bernardo J, Venkataramanan R, Sterling TR; ATS (American Thoracic Society) Hepatotoxicity of Antituberculosis Therapy Subcommittee.

Am J Respir Crit Care Med. 2006 Oct 15;174(8):935-52. Review.

PMID:
17021358
41.

Callipyge mutation affects gene expression in cis: a potential role for chromatin structure.

Murphy SK, Nolan CM, Huang Z, Kucera KS, Freking BA, Smith TP, Leymaster KA, Weidman JR, Jirtle RL.

Genome Res. 2006 Mar;16(3):340-6. Epub 2006 Jan 13.

42.

Mannose 6-phosphate receptors in an ancient vertebrate, zebrafish.

Nolan CM, McCarthy K, Eivers E, Jirtle RL, Byrnes L.

Dev Genes Evol. 2006 Mar;216(3):144-51. Epub 2006 Jan 13.

PMID:
16411117
43.

Use of rapid genomic deletion typing to monitor a tuberculosis outbreak within an urban homeless population.

Freeman R, Kato-Maeda M, Hauge KA, Horan KL, Oren E, Narita M, Wallis CK, Cave D, Nolan CM, Small PM, Cangelosi GA.

J Clin Microbiol. 2005 Nov;43(11):5550-4.

44.

Controlling tuberculosis in the United States. Recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America.

Taylor Z, Nolan CM, Blumberg HM; American Thoracic Society; Centers for Disease Control and Prevention; Infectious Diseases Society of America.

MMWR Recomm Rep. 2005 Nov 4;54(RR-12):1-81. Erratum in: MMWR Morb Mortal Wkly Rep. 2005 Nov 18;54(45):1161.

45.

Phase transition behavior, protein adsorption, and cell adhesion resistance of poly(ethylene glycol) cross-linked microgel particles.

Nolan CM, Reyes CD, Debord JD, GarcĂ­a AJ, Lyon LA.

Biomacromolecules. 2005 Jul-Aug;6(4):2032-9.

PMID:
16004442
46.

Abnormal postnatal maintenance of elevated DLK1 transcript levels in callipyge sheep.

Murphy SK, Freking BA, Smith TP, Leymaster K, Nolan CM, Wylie AA, Evans HK, Jirtle RL.

Mamm Genome. 2005 Mar;16(3):171-83.

PMID:
15834634
47.

Doxorubicin uptake and release from microgel thin films.

Serpe MJ, Yarmey KA, Nolan CM, Lyon LA.

Biomacromolecules. 2005 Jan-Feb;6(1):408-13.

PMID:
15638546
48.

Insulin-like growth factor (IGF) signalling is required for early dorso-anterior development of the zebrafish embryo.

Eivers E, McCarthy K, Glynn C, Nolan CM, Byrnes L.

Int J Dev Biol. 2004 Dec;48(10):1131-40.

49.

Thermally modulated insulin release from microgel thin films.

Nolan CM, Serpe MJ, Lyon LA.

Biomacromolecules. 2004 Sep-Oct;5(5):1940-6.

PMID:
15360309
50.

Phylogenetic footprint analysis of IGF2 in extant mammals.

Weidman JR, Murphy SK, Nolan CM, Dietrich FS, Jirtle RL.

Genome Res. 2004 Sep;14(9):1726-32.

Supplemental Content

Loading ...
Support Center